PANOPTES
Panoptes is a privately held biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases.
PANOPTES
Industry:
Biotechnology Medical Pharmaceutical
Address:
Wiener Neustadt, Niederosterreich, Austria
Country:
Austria
Website Url:
http://www.panoptes-pharma.com
Status:
Active
Contact:
+43 1 8905697
Email Addresses:
[email protected]
Similar Organizations
TissueGene
TissueGene is a biopharmaceutical company focused on developing regenerative therapies for the treatment of various orthopedic disorders.
Official Site Inspections
http://www.panoptes-pharma.com
- Host name: 172.67.183.242
- IP address: 172.67.183.242
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Panoptes"
Panoptes Pharma - Innovationen in Ophthalmologie und Medizin
Panoptes Pharma ist ein internationales Biotechnologieunternehmen, das fortschrittliche Lösungen für die Behandlung von Augenkrankheiten und anderen medizinischen Problemen …See details»
EyeGate Pharma Announces Transformative Acquisition of …
Dec 21, 2020 Expands Pipeline Beyond Ophthalmology with PP-001, a Clinical Stage, Best-in-Class DHODH Inhibitor PP-001 Leverages a Validated Immune Modulating Mechanism …See details»
EyeGate Pharma Announces Transformative Acquisition of …
The privately held biotech company Panoptes Pharma GmbH was founded by Dr. Franz Obermayr and Dr. Stefan Sperl and is located in Vienna, Austria. The highly experienced team …See details»
Panoptes Pharma - PitchBook
Panoptes Pharma General Information Description. Provider of molecule-based therapies intended to help in the treatment of severe eye diseases. The company's molecule-based …See details»
Kiora Pharmaceuticals - Craft
Kiora Pharmaceuticals (formerly known as Panoptes Pharma) is a clinical-stage biotech company focused on developing small molecule-based therapies for the treatment of severe eye …See details»
Panoptes Pharma - Funding, Financials, Valuation & Investors
Nov 2, 2015 Seed Round - Panoptes Pharma . 3: obfuscated. obfuscated. Arax Capital Partners: Investors. Edit Investors Section. Number of Lead Investors 1. Number of Investors 3. …See details»
Panoptes Pharma - VentureRadar
Panoptes intends to develop PaniJect and PaniDrop up to proof-of-concept studies in different indications in ophthalmology. Panoptes Pharma is developing products based on the novel …See details»
EyeGate Pharma Announces Acquisition of Panoptes Pharma
Dec 21, 2020 EyeGate Pharmaceuticals announced the acquisition of Panoptes Pharma, a privately-held clinical stage biotech company focused on developing a novel proprietary small …See details»
The Strategy Behind EyeGate’s Acquisition of Panoptes
With the acquisition of Vienna-based biotech Panoptes Pharma, Eye Gate Pharmaceuticals has expanded its pipeline of nonsteroidal products targeting ocular inflammation by adding Panoptes’ PP-001, ... Panoptes’ Markets The …See details»
Detail - LISA: Advancing Austrian life science
Dec 21, 2020 The privately held biotech company Panoptes Pharma GmbH was founded by Dr. Franz Obermayr and Dr. Stefan Sperl and is located in Vienna, Austria. The highly …See details»
Panoptes Pharma - Ophthalmology Innovation Source
Panoptes Pharma Franz Obermayr gives a short overview of Panoptes Pharma founded only last year, covering only one of their developments: C0C01 for local treatment in ophthalmology. …See details»
DLA Piper
Jan 4, 2021 DLA Piper has advised Austrian biotech company Panoptes Pharma (Panoptes) on its acquisition by EyeGate Pharmaceuticals (EyeGate), a clinical stage company focused on …See details»
EyeGate Pharma Announces Transformative Acquisition of …
Dec 21, 2020 The privately held biotech company Panoptes Pharma GmbH was founded by Dr. Franz Obermayr and Dr. Stefan Sperl and is located in Vienna, Austria. The highly …See details»
EyeGate Pharma Announces Transformative Acquisition of …
Dec 21, 2020 The privately held biotech company Panoptes Pharma GmbH was founded by Dr. Franz Obermayr and Dr. Stefan Sperl and is located in Vienna, Austria. The highly …See details»
EyeGate Pharma Announces Transformative Acquisition of …
Dec 21, 2020 --EyeGate Pharmaceuticals, Inc., a clinical stage company focused on developing products for treating disorders of the eye, today announced the acquisition of Panoptes …See details»
The Austrian biotech company Panoptes Pharma GmbH has a …
Mar 25, 2020 Panoptes Pharma GmbH has developed PP-001 for the treatment of severe eye diseases and has already completed phase 2 clinical studies. So far, the drug is well tolerated. …See details»
EyeGate Pharma Announces Transformative Acquisition of
Dec 21, 2020 The privately held biotech company Panoptes Pharma GmbH was founded by Dr. Franz Obermayr and Dr. Stefan Sperl and is located in Vienna, Austria. The highly …See details»